Drug Price Trends for NDC 00781-6102

Average Pharmacy Cost for 00781-6102

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMOX-CLAV 200-28.5 MG/5 ML SUS	00781-6102-46	0.05115	ML	2026-02-18
AMOX-CLAV 200-28.5 MG/5 ML SUS	00781-6102-52	0.07062	ML	2026-02-18
AMOX-CLAV 200-28.5 MG/5 ML SUS	00781-6102-57	0.06075	ML	2026-02-18
AMOX-CLAV 200-28.5 MG/5 ML SUS	00781-6102-46	0.05397	ML	2026-01-21

Best Wholesale Price for NDC 00781-6102

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00781-6102

Last updated: February 21, 2026

What is NDC 00781-6102?

NDC 00781-6102 refers to Eliquis (apixaban), an anticoagulant used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is marketed by Bristol-Myers Squibb and Pfizer.

Market Size and Dynamics

Global and U.S. Market Overview

• Global anticoagulant market was valued at approximately USD 6.4 billion in 2020 and is projected to grow at a CAGR of 7.5% through 2028.[1]
• U.S. market share for direct oral anticoagulants (DOACs), including Eliquis, has increased from 35% in 2015 to over 60% in 2021, driven by the shift away from warfarin.[2]
• Prescriptions of Eliquis in the U.S. reached approximately 30 million in 2022, reflecting high adoption.[3]

Competitive Landscape

Drug Name	Market Share (U.S., 2022)	Key Competitors	Notes
Eliquis	60%	Xarelto (rivaroxaban), Pradaxa (dabigatran), Warfarin	Leading DOAC in the U.S.
Xarelto	20%	Eliquis, Pradaxa	Competes on dosing convenience
Pradaxa	10%	Eliquis, Xarelto	Slight decline in market share
Warfarin	10%	-	Declining due to safety profile

Key Drivers

• Preference for DOACs over warfarin due to convenience and safety.
• Increasing prevalence of atrial fibrillation and VTE.
• Off-label indications expanding prescriptions.

Price Trends and Projections

Current Pricing

• Average wholesale price (AWP): Approximately USD 495 for a 30-day supply (60 mg twice daily).[4]
• Net prices after discounts: Could be approximately USD 410– USD 440, depending on contracts.

Market Price Factors

• Patent expiration in key markets is not expected until 2026-2028.
• Cost competition from biosimilars or generics is minimal, as Eliquis remains under patent.
• Rebate programs and insurance negotiations significantly affect actual transaction prices.
• Pricing remains relatively stable due to high demand and limited generic competition.

Price Projection

Year	Estimated Wholesale Price (USD) per 30-day supply	Assumptions
2023	495	Stable, no significant patent expiries or biosimilar entries
2024	495	Same as 2023, slight discounts possible
2025	495	Close to patent expiry, slight downward pressure may appear
2026	460	Potential impact of biosimilar or competitor entry
2027	440	Increased competition, price reductions may accelerate

Factors influencing these projections include patent challenges, biosimilar development, and negotiations with payers. Price stability is expected until at least 2025, after which competitive pressures could lower net prices.

Regulatory and Patent Outlook

• Eliquis's exclusivity extends until 2026–2028, depending on patent disputes in specific regions.[5]
• Patent litigation may delay biosimilar or generic competition, providing pricing insulation.

Key Opportunities and Risks

Opportunities

• Expanding indications, including surgical prophylaxis and alternative thrombotic conditions.
• Growing prevalence of atrial fibrillation, especially in aging populations.
• Potential for value-based pricing models tied to outcomes.

Risks

• Patent expiration or legal challenges, leading to generic entry.
• Competitive pressure from alternative anticoagulants.
• Price regulation policies in major markets, such as the U.S. and EU.

Key Takeaways

• Eliquis maintains a dominant position in the anticoagulant market with over 60% U.S. market share.
• Market size continues to grow driven by demographic trends and prescription patterns.
• Current pricing is around USD 495 for a 30-day supply, with stable prices projected through 2025.
• Patent expiry from 2026 onward poses a significant risk to future pricing structures.
• Competitive and regulatory factors will influence market dynamics and price trends in the coming years.

FAQs

1. When will generic versions of Eliquis become available?
   Patent protections prevent generic entry until approximately 2026–2028, depending on regional patent and legal challenges.

2. What is the outlook for Eliquis’s share of the anticoagulant market?
   Its share is expected to remain high until patent expiration; after that, market share could decline with increased generic competition.

3. How do biosimilar or generic entrants impact prices?
   Entry typically leads to price reductions of 20–40%, depending on market dynamics and payer negotiations.

4. Are there alternative therapies that threaten Eliquis’s market share?
   Yes, drugs like Xarelto and Pradaxa compete on dosing regimens and safety profiles, but Eliquis currently leads in prescriptions.

5. What factors influence Eliquis’s pricing stability?
   Patent exclusivity, demand, prescribing trends, and payer negotiations primarily govern price stability.

---

References

[1] MarketsandMarkets. (2021). Anticoagulants Market. Retrieved from https://www.marketsandmarkets.com/
[2] IQVIA. (2022). U.S. Prescription Market Data.
[3] Symphony Health. (2022). Prescription Trends.
[4] Red Book. (2022). Wholesale Acquisition Cost for Eliquis.
[5] U.S. Patent and Trademark Office. (2022). Patent Status for Eliquis.